These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 19883882)

  • 101. Experimental and investigational therapies for chemotherapy-induced anemia.
    Testa U; Castelli G; Elvira P
    Expert Opin Investig Drugs; 2015; 24(11):1433-45. PubMed ID: 26359222
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Ten years of meta-analyses on erythropoiesis-stimulating agents in cancer patients.
    Tonia T; Bohlius J
    Cancer Treat Res; 2011; 157():217-38. PubMed ID: 21052959
    [TBL] [Abstract][Full Text] [Related]  

  • 103. The effect of erythropoiesis-stimulating agents on systolic and diastolic blood pressure in hemodialysis patients: A systematic review and meta-analysis of clinical trials.
    Karimi Z; Raeisi Shahraki H; Mohammadian-Hafshejani A
    Med Clin (Barc); 2024 May; 162(10):e43-e51. PubMed ID: 38433073
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Statins and resistance to erythropoiesis-stimulating agents: are the two associated?
    Granger Vallée A; Canaud B
    Nephrol Dial Transplant; 2011 Aug; 26(8):2715-6; author reply 2716-7. PubMed ID: 21602186
    [No Abstract]   [Full Text] [Related]  

  • 105. Artificial intelligence supported anemia control system (AISACS) to prevent anemia in maintenance hemodialysis patients.
    Ohara T; Ikeda H; Sugitani Y; Suito H; Huynh VQH; Kinomura M; Haraguchi S; Sakurama K
    Int J Med Sci; 2021; 18(8):1831-1839. PubMed ID: 33746600
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Response to "Warning flags for erythropoiesis-stimulating agents and cancer-associated anemia".
    Littlewood TJ
    Oncologist; 2007 Aug; 12(8):1031-2; author reply 1032-4. PubMed ID: 17766663
    [No Abstract]   [Full Text] [Related]  

  • 107. [Erythropoiesis-stimulating agents in congestive heart failure patients].
    Robles Perez-Monteoliva NR; Macías Núñez JF; Herrera Pérez de Villar J
    Med Clin (Barc); 2014 Mar; 142(5):215-8. PubMed ID: 24012446
    [TBL] [Abstract][Full Text] [Related]  

  • 108. [Use of Venofer in management of anemia in cancer patients].
    Makhnova EV; Livshits ME; Gershanovich ML
    Vopr Onkol; 2006; 52(5):552-5. PubMed ID: 17168365
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Managing Chemotherapy-Induced Anemia with Erythropoiesis-Stimulating Agents Plus Iron.
    Whitehead L
    Am J Nurs; 2017 May; 117(5):67. PubMed ID: 28448368
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Prognostic impact of the combination of erythropoiesis-stimulating agents to cancer treatment: literature review.
    Boulaamane L; Goncalves A; Boutayeb S; Viens P; M'rabti H; Bertucci F; Errihani H
    Support Care Cancer; 2013 Aug; 21(8):2359-69. PubMed ID: 23775155
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Are erythropoiesis-stimulating agents beneficial for anemia in chronic heart failure patients?
    Araneda D; Rada G
    Medwave; 2016 Nov; 16(Suppl5):e6607. PubMed ID: 27922585
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Erythropoiesis-stimulating agents on trial: are higher dosages causing harm?
    Chaknos CM; Berns JS
    Am J Kidney Dis; 2013 Jan; 61(1):6-8. PubMed ID: 23245737
    [No Abstract]   [Full Text] [Related]  

  • 113. Erythropoiesis-stimulating agent hyporesponsiveness in dialysis patients: be aware of subclinical hypothyroidism.
    Su SC; Wu CC; Chen CC
    Nephrology (Carlton); 2013 Jun; 18(6):478. PubMed ID: 23710933
    [No Abstract]   [Full Text] [Related]  

  • 114. Chronic kidney disease: Are elevated doses of ESAs associated with adverse outcomes?
    Eckardt KU
    Nat Rev Nephrol; 2010 Oct; 6(10):566-8. PubMed ID: 20871637
    [No Abstract]   [Full Text] [Related]  

  • 115. A recurrent neural network approach to predicting hemoglobin trajectories in patients with End-Stage Renal Disease.
    Lobo B; Abdel-Rahman E; Brown D; Dunn L; Bowman B
    Artif Intell Med; 2020 Apr; 104():101823. PubMed ID: 32499002
    [TBL] [Abstract][Full Text] [Related]  

  • 116. New ESA to be available for dialysis patients.
    Thompson CA
    Am J Health Syst Pharm; 2012 May; 69(9):731. PubMed ID: 22517015
    [No Abstract]   [Full Text] [Related]  

  • 117. Erythropoiesis-stimulating agents in ovarian cancer patients receiving chemotherapy: to treat or not to treat?
    Marchetti C; Palaia I; Benedetti Panici P
    Int J Gynecol Cancer; 2013 Jun; 23(5):783-4. PubMed ID: 23694979
    [No Abstract]   [Full Text] [Related]  

  • 118. Intolerability of cobalt salt as erythropoietic agent.
    Ebert B; Jelkmann W
    Drug Test Anal; 2014 Mar; 6(3):185-9. PubMed ID: 24039233
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Hematopoietic growth factors in lung cancer.
    Genova C; Rijavec E; Grossi F
    Curr Opin Oncol; 2016 Mar; 28(2):135-44. PubMed ID: 26742020
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Significant further evidence to bolster the link between epoetin and strokes in chronic kidney disease and cancer.
    Goldsmith DJ; Covic AC
    Kidney Int; 2011 Aug; 80(3):237-9. PubMed ID: 21760602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.